

Research Article

Antihyperlipidemic and Antioxidative Potentials of Onion (*Allium cepa* L.) Extract Fermented with a Novel *Lactobacillus casei* HD-010

Woong-Suk Yang,^{1,2} Jin-Chul Kim,³ Jae Yong Lee,⁴
Cheorl-Ho Kim ⁵ and Cher-Won Hwang ⁶

¹Nodaji Co., Ltd., Pohang, Gyeongbuk, Republic of Korea

²School of Life Sciences and Biotechnology, Kyungpook National University, Daegu, Republic of Korea

³Natural Constituents Research Center, Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, Republic of Korea

⁴Department of Advanced Aerospace Materials Engineering, Kyungwoon University, Gumi, Gyeongbuk, Republic of Korea

⁵Department of Biological Sciences, College of Science, SungKyunKwan University, Seoburo 2066, Jangan-Gu, Suwon 16419, Republic of Korea

⁶Department of AGEE, Handong University, Pohang, Gyeongbuk, Republic of Korea

Correspondence should be addressed to Cheorl-Ho Kim; chkimbio@skku.edu and Cher-Won Hwang; chowon@handong.edu

Received 30 August 2018; Revised 4 January 2019; Accepted 10 February 2019; Published 3 March 2019

Academic Editor: Wen-yi Kang

Copyright © 2019 Woong-Suk Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this study was to investigate antihyperlipidemic and antioxidative potentials of onion (*Allium cepa* L.) extract fermented with a novel *Lactobacillus casei* HD-010. In general, fermented onion extract is used for its antioxidative activity (ORAC), inhibitory effect on adipocytes differentiation, quercetin contents, and antihyperlipidemic activities. However, the effect of fermented onion extract on hyperlipidemia after oral administration using ApoE-deficient mice has not been reported yet. To understand the effect of fermented onion extract on hyperlipidemia, we used benzaifibrate (10 mg/kg, bw/day) as a positive control in the present study. Serum was collected every week to analyze levels of low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG), and cholesterol, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity, and cholesterol ester transport protein (CETP) activity. In the fermented onion-treated group, HDL level was significantly increased while levels of TG and LDL were significantly decreased compared to those in the control group. In addition, the inhibition activity of HMG-CoA reductase was increased 20% in the fermented onion-treated group at 100 mg/kg. CETP activity has been observed to be significantly inhibited in the fermented onion-treated groups compared to that in the control group. These results suggest that fermented onion has a preventive/therapeutic effect on hyperlipidemic disease. It might have potential to be developed as a functional food.

1. Introduction

Recently, food consumption pattern has considerably changed from traditional fermented food-based intake (Kimchi, fermented soy bean, etc.) to fat containing westernized diet (meat, fats, etc.) in Asia, including Korea [1–3]. Westernized food intake pattern is known to increase risks of obesity, high blood pressure, diabetes, and hyperlipidemia [4–7]. Hyperlipidemia is a risk factor of cardiovascular diseases. Controlling hypercholesterolemia is important to prevent

hyperlipidemia. Reducing triglyceride level in blood stream is one of treatments for patients with cardiovascular related disease through inducing LDL receptors and limiting VLDL secretion with certain drugs [8].

There are several medicines for reducing hyperlipidemia symptoms, such as HMG-CoA reductase inhibitor (statins), PPAR-alpha activator (fibrate), CETP inhibitor, bile acid sequestrants, and ACAT inhibitor [9–11]. However, long-term treatment with these medications has side effects. Thus, many studies have tried to increase drug efficiency [12, 13].

TABLE 1: Identification of isolated bacteria by 16s-rRNA.

Code Name	Results	Homology (%)
HD-001	<i>Bradyrhizobium japonicum</i>	97
HD-002	<i>Bacillus</i> sp.	95
HD-003	<i>Bacillus</i> sp.	95
HD-004	<i>Bacillus clausii</i>	89
HD-005	<i>Janibacter</i> sp.	96
HD-006	<i>Bacillus clausii</i>	90
HD-007	<i>Burkholderia tropica</i>	100
HD-008	<i>Bacillus</i> sp.	97
HD-009	<i>Paenibacillus</i> sp.	100
HD-010	<i>Lactobacillus casei</i>	100

[Ref. <https://blast.ncbi.nlm.nih.gov/Blast.cgi>]

Reducing cholesterol concentration in blood is an important research issue for functional food and drug development to decrease the risk of cardiovascular related diseases. Natural components from plant or organisms are potential candidates to decrease the risk of disease outbreak. Onion (*Allium cepa* L.) has been used for decreasing blood cholesterol levels [14]. In Asia, it was traditionally used as a medicine due to its fever-reducing, antiparasitic, detoxification, and intestinal anti-inflammation effects [5, 15–17]. Major compounds in onion are flavonoids (quercetin, quercitrin, and rutin) and sulfuric compounds (allyl propyl disulfide, diallyl disulfide) with health improving effects [18]. Another method to reduce cholesterol is by using *Lactobacillus* for fermentation. *Lactobacillus* has been studied for its cholesterol-reducing effect. Klaver et al. [19] have reported that *Lactobacillus* can deconjugate bile acid and inhibit the function of cholesterol. However, the effect of fermented onion extract on hyperlipidemia after oral administration using ApoE-deficient mice has not been reported yet. Therefore, the purpose of this study was focused on antihyperlipidemic and antioxidative potentials of fermented onion (*Allium cepa* L.) with a novel *Lactobacillus casei* HD-010 in lipid metabolism.

2. Materials and Methods

2.1. Selection of Bacterial Strain and Culture Condition. Ten strains were identified from fermented onion and the main strain was *Lactobacillus casei* HD-010 (Table 1). We used *L. casei* KCTC 2180 from Korean Collection for Type Cultures as a positive control. The identified strain *L. casei* HD-010 was cultured at 30°C for 10 days to ferment onion extract. Onion extract was prepared with minced clean onion after washing with double distilled water three times. Autoclaved onion extract at 121°C for 15 minutes was used for fermentation. Strain identification medium was prepared using 5.5% MRS broth (Difco, France) with 2.0% agar (Difco, France). Liquid culture media was prepared as the strain identification media without 2.0% agar.

2.2. Preparation of Fermented Onion Extract. A 30-liter fermenter (Biostat C Plus, Sartorius, Sweden) [20, 21] was used for onion extract fermentation with 100% onion extract

under sterile condition. After cooling the onion extract, 1% HD-010 which was incubated at 37°C with shaking (200 rpm) for 24 hours inoculated into the fermenter and cultured at 37°C with shaking (25 rpm) for 10 days. After filtering the fermented onion extract with a filter (0.2 μm pore size), the extract was lyophilized (PVTFD20RS, Ilshin Lab. Co. Ltd., Korea) and kept at -80°C until the experiment was performed. As a positive control, *L. casei* KCTC 2180 was used. It was prepared with the same method as *L. casei* HD-010.

2.3. Assay of Oxygen Radical Absorbance Capacity (ORAC). Antioxidant capacities of fermented onions, layers of organic solvents, fractions, and subfractions were determined using ORAC assay as described by Gillespie et al. [22]. Briefly, samples or Trolox (0, 6.25, 12.5, 25, 50, and 100 μg/ml) were mixed with phosphate buffered saline (75 mmol/L, pH 7.4, Thermofisher scientific, Waltham, MA, USA). After the addition of β-phycoerythrin (0.2 mmol/L) and 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH, 200 mmol/L, Wako Pure Chemical Industries, Ltd., Osaka, Japan) as radical generators were added to wells of a 96-well plate. Fluorescence was measured with a fluorescence ELISA reader (VICTOR®, PerkinElmer, USA) every two minutes for sixty minutes (excitation wavelength: 535 nm, emission wavelength: 590 nm). The equation used to obtain AUC (area under the curve) was as follows:

$$\text{AUC} = 1 + \left(\frac{f_1}{f_0}\right) + \left(\frac{f_2}{f_0}\right) + \left(\frac{f_3}{f_0}\right) + \dots + \left(\frac{f_{59}}{f_0}\right) + \left(\frac{f_{60}}{f_0}\right) \quad (1)$$

where f_0 was the initial fluorescence reading at 0 min and f_i was the fluorescence reading at i (from 1 to 60) minutes.

$$\text{Relative ORAC value} = \left[\frac{(\text{AUC}_{\text{sample}} - \text{AUC}_{\text{blank}})}{(\text{AUC}_{\text{Trolox}} - \text{AUC}_{\text{blank}})} \right] \times \left(\frac{\text{Molarity of Trolox}}{\text{Molarity of sample}} \right) \quad (2)$$

2.4. Adipocyte Cell Culture and Differentiation. We purchased 3T3-L1 cell lines from the American Type Culture Collection (ATCC, USA). 3T3-L1 preadipocytes cells were plating into 96-well plates at a density of 1×10^4 cells per well. And cultured at 37°C with 5% CO₂ in Dulbecco's Modified Eagle Media (DMEM, Gibco, Invitrogen, USA) medium supplemented with 10% newborn calf serum (Gibco, Invitrogen, USA) and 100 U/ml penicillin-streptomycin (Gibco, Invitrogen, USA). Next, 3T3-L1 preadipocytes cells were cultured in differentiation medium (MDI) containing 10% fetal bovine serum (FBS, Gibco), 10 µg/ml insulin (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich), and 1 µM dexamethasone (Sigma-Aldrich). Two days after stimulation with differentiation inducer (MDI, including 0.5 mM IBMX, 1 µM dexamethasone, and 10 µg/ml insulin), the medium was switched to DMEM containing 10% FBS and 10 µg/ml insulin. Two days later, the medium was changed again to 10% FBS/DMEM. Cells were cultured in 10% FBS/DMEM every two days. Full differentiation was achieved by day 8. Onion extract samples were added to 3T3-L1 cells culture at various concentrations (6.25 ~ 100 µg/ml) on four days after differentiation induction.

Intracellular lipid content was measured in 96-well plates using AdipoRed™ assay reagent (Cambrex, MA, USA). On day 8, the treatment medium was removed and the cells were fixed in a 4% formaldehyde solution at room temperature (25°C) for 5 hrs. After rinsing cells with PBS, each well was added with 200 µl PBS and 5 µl of AdipoRed reagent. Following incubation at room temperature for 10 min, plates were measured with a fluorescence ELISA reader (VICTOR®, PerkinElmer, USA) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. Values from each group were used to calculate the 50% effective inhibition concentration (EC₅₀) for reducing adipocyte differentiation. As positive controls, bezafibrate and simvastatin were used.

2.5. Separation and Fractionation of Onion Extract Fermented with *L. casei* HD-010. Freeze-dried fermented onion extracts were resuspended in distilled water and partitioned with four different organic solvents (*n*-hexane, CH₂Cl₂, ethyl acetate, and *n*-butanol) and residual H₂O. These fractions were subjected to decompression enriching and freeze-drying to remove residual solvent. The CH₂Cl₂ layers were sequentially applied to HP-20, silica gel and RP-C₁₈ open column chromatography under the same column conditions (3.8 x 60 cm, 300 g) [23–25] to obtain the active compound from fermented onions with *L. casei* HD-010 (LFAc).

2.6. Quercetin Contents. Quercetin contents in fermented onion extracts were quantitatively analyzed [26] by analytical HPLC (Shimadzu CBM-20A Network LC system with LC-6AD pump, SPD-M20APDA detector, equipped with an SIL-10AF series automated liquid sampler). An Eclipse Plus-C₁₈ column (Agilent, 3.0 x 100 mm, 0.35 µm) was used at the following conditions: flow rate, 1.0 ml/min; total run length, 30 minutes; mobile phase 90% ACN plus 0.02 M KH₂PO₄ (pH 2.0 with H₃PO₄); injection volume of samples or STD, 20 µl; and wavelength, 372 nm. Quercetin (Q4951) was used as

comparative derivative standard (CAS No. 117-39-5, Sigma-Aldrich, USA)

2.7. Animal Experiments. Male ApoE-deficient mice (five weeks old) were supplied from Central Laboratory Animal Inc. in Korea and housed at 23 ± 0.5°C with 55 ± 7% humidity and light-dark cycle (12 hrs: 12 hrs). All animals were acclimated at least one week. They were caged and fed a low fat, low cholesterol control diet D12336 (Central Laboratory Animal Inc., Seoul, Korea).

All animal studies were performed in a pathogen-free barrier zone at Kyungpook National University. All procedures used in this study were approved by the Animal Care and Use Committee of Kyungpook National University (IACUC approval number: KNU2012-136).

The control group was fed with a high fat diet. The positive control group was fed with bezafibrate (10 mg/kg). Fermented onion extract was fed into three groups with different amounts by oral administration in 0.5 ml of saline (low dose, 25 mg/kg; medium dose, 50 mg/kg; and high dose, 100 mg/kg). Saline alone group was used as a negative control (N=10/group) [24, 27]. Animal experiment design of this study is shown in Figure 1.

2.7.1. Lipid Contents Measurement. Blood was collected from mouse by retroorbital sinus bleeding method using intra-orbital venous plexus every week for six weeks. Blood samples were incubated at room temperature for 30 minutes and centrifuged at 600 g for 10 minutes at 4°C. Sera samples were prepared and kept at -80°C until assay. HMG-CoA reductase and CETP inhibition activities were measured using sera samples collected at the last experimental point (6th week samples). HMG-CoA reductase and CETP inhibition activities were measured using HMG-CoA reductase assay kit (Sigma, USA) and CETP assay kit (Biovision, USA), respectively. Serum was measured for contents of total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglyceride (TG) using Asan kit (Asan medical company, Korea) and a Beckman Coulter biochemical analyzer.

2.8. Statistical Analysis. The results are presented as mean ± standard deviation (mean ± SD). The statistical analyses of data were determined by using two-tailed Student's *t*-test.

3. Results and Discussion

3.1. Fermented Onion Exhibits Antioxidative Activity. We have investigated the anti-oxidative activity of onion extract fermented with *L. casei* HD-010 (LFAc) by ORAC assay. LFAc had higher ORAC value than Trolox, a positive control (ORAC_{PE} of LFAc extract = 1.02).

In order to determine which fractions of the onion extracts fermented with *L. casei* HD-010 contained antioxidative ingredients, we further separated the extract using four different organic solvents as described in the Materials and Methods section. The LFAc-EtOAc fractions had the highest ORAC value (ORAC_{PE} of LFAc-EtOAc = 1.12) (Figure 2), suggesting that the EtOAc fractions of the onion extract




FIGURE 1: Animal experiment design.

fermented with *L. casei* HD-010 (LFAc) contained an antioxidative component. This result suggests that onion extract fermented with *L. casei* HD-010 (LFAc) has antioxidative activity.

3.2. Adipocyte Differentiation Inhibition. Fermented onion with *L. casei* HD-010 (LFAc) showed an inhibitory effect on adipocytes differentiation compared to fresh onion or autoclaved onion (> 20%). The inhibitory effect of LFAc was specifically observed in the CH₂Cl₂ layer (> 45%) (Figure 3). As a positive control, benzaifibrate had no effect on differentiation. However, simvastatin treatment showed more than 90% of differentiation inhibition. Therefore, LFAc has an inhibitory function by blocking HMG-CoA reductase activity.

3.3. Dichloromethane Layers of Onion Extract Fermented with *L. casei* HD-010 (LFAc) Have Both Adipocytes Differentiation Inhibiting and Antioxidative Effects. In order to purify and identify the active compound in LFAc for the induction of physiological activity, CH₂Cl₂ layers were subjected to several isolation procedures (HP-20, Silica gel, and RP-C₁₈ open column). HLFac-30 and SLFAc-4 fractions with strong adipocyte differentiation inhibiting activities were sequentially obtained (date not shown) after further isolation of SLFAc-4 fractions in an RP-C₁₈ open column.

In order to investigate hyperlipidemia inhibitory function after LFAc, MC fraction was subjected to HP-20, silica gel, and RP-18 open chromatography. Antioxidant and adipocytes differentiation inhibition effects were observed for LFAc-HP3 fraction from HP-20, LFAc-S4 fraction from silica gel, and LFAc-C3 from C1 (Table 2).

3.4. Quercetin Contents. Thin layer chromatography (TLC) was used to separate components from raw onion extract




FIGURE 2: Antioxidative activities of fractions of onion extract fermented with *L. casei*HD-010 (LFAc) using organic solvents. Oxygen Radical Absorbance Capacity (ORACPE) values were obtained in the antioxidant assay using various organic solvent fractions. Trolox was used as a positive control (ORACPE value was 1.00). Data are presented as mean \pm SD (n = 3). #*p*<0.05 versus control group (FO treated group); ##*p*<0.05 versus control group (AO treated group); ###*p*<0.05 versus LFAc treated group; **p*<0.05 versus positive control group (*L. casei* KCTC 2180 treated group); ***p*<0.05 versus positive control (Trolox treated group); FO, fresh onion; AO, autoclave onion; LFAc, fermented onion with *L. casei* HD-010; Hx, *n*-hexane; CH₂Cl₂, dichloromethane; EtOAc, ethyl acetate; BuOH, *n*-butanol; *L. casei* KCTC 2180, fermented onion with *L. casei* KCTC 2180.

(FO), sterilized onion extract (AO), and fermented onion extract (LFAc). The pattern was not different between samples and four major spots were found (data not shown). LFAc-C4 fraction showed the best adipocytes differentiation inhibitory effect and an effective single fraction was identified. Quercetin, one of major onion components,

TABLE 2: Adipocyte differentiation inhibition and antioxidative activities of subfractions from LFAc_S4 using C₁₈ open column.

Samples	Inhibition (EC ₅₀ = μ g/ml)	ORAC _{PE}
LFAc-CH ₂ Cl ₂	53.25	1.10 \pm 0.015**
LFAc-C1	53.41	1.06 \pm 0.028
LFAc-C2	56.56	1.04 \pm 0.013
LFAc-C3	40.25*	1.15 \pm 0.021**
LFAc-C4	42.98*	1.16 \pm 0.057**
LFAc-C5	>100	ND
Trolox	ND	1.00 \pm 0.017

Data are presented as mean \pm SD (n = 3); * p <0.05 versus control group (PBS treated group); ** p <0.05 versus positive control (Trolox treated group). ND (not detected).




FIGURE 3: Adipocyte differentiation inhibition of onion (*Allium cepa* L.) extract fermented with *L. casei* HD-010 (LFAc). Data are presented as mean \pm SD (n = 3). * p <0.05 versus FO, AO, LFAc, or LFAc-Hx treated group; # p <0.05 versus positive control (benzaifibrate treated group); ## p <0.01 versus positive control (benzaifibrate treated group). FO, fresh onion; AO, autoclave onion; LFAc, fermented onion with *L. casei* HD-010; Hx, *n*-hexane; CH₂Cl₂, dichloromethane; EtOAc, ethyl acetate; BuOH, *n*-butanol.

was identified from LFAc-C4 fraction. FO, AO, LFAc, and LFAc-CH₂Cl₂ were examined with HPLC. Quercetin contents in these fractions were FO, 3.90 \pm 0.041 mg/ml; AO, 7.13 \pm 0.009 mg/ml; LFAc, 2.89 \pm 0.064 mg/ml; and LFAc-CH₂Cl₂, 20.53 \pm 0.304 mg/ml. Quercetin content was not altered by fermentation procedure. However, following fermentation with probiotics, quercetin content was enhanced by almost 10-fold in LFAc-CH₂Cl₂ (Figure 4).

3.5. Animal Test

3.5.1. Body Weight. The effect of fermented onion extract on body weight was tested for six weeks using mice with a high fat diet. Any significant decrease in body weight has been observed in the fermented onion extract feeding group. Dietary fiber, flavonoids, and sulfuric components in onion efficiently reduced their body weights compared to the high fat diet alone group (data not shown). This result suggests that oral administration of fermented onion extract has no direct effect on body weight, consistent with other studies [18].

3.5.2. Serum Lipid Contents Measurement. Serum was collected every week for six weeks and assessed for changes




FIGURE 4: Quantity of quercetin contents in onion (*Allium cepa* L.) extract with or without fermentation using HPLC analysis. Data are presented as mean \pm SD (n = 3). FO, fresh onion; AO, autoclave onion; LFAc, fermented onion with *L. casei* HD-010; CH₂Cl₂, dichloromethane.

in LDL-C, HDL-C, TG, and TC contents. At the end of the experiment, serum was tested for HMG-CoA reductase and CETP inhibition effect. Fermented onion extract feeding groups (low, medium, and high) showed significant decreases in LDL-C level from the fifth week. The medium and high fermented onion extract feeding groups showed continuous decrease in their body weights (Table 3). In addition, HDL-C level was increased from the first week until the sixth week after administration (Table 4). The LSP-11 supernatant feeding group showed considerable changes in HDL-C and LDL-C levels at the third and fifth weeks. These data suggest that fermented onion extract might have synergic effects on functions of secondary metabolites from *Lactobacillus casei* HD-010.

Serum TG level was slightly decreased in all groups compared to that in the control. However, such decrease was not statistically significant. Specifically, high fermented onion extract fed group showed significant decrease in TG level at the first, second, third, and fifth week (Table 5). TC level was reduced in the fermented onion extract fed group from the fifth week (Table 6). However, the positive control group that was fed with benzaifibrate and *Lactobacillus* supernatant did not show any significant difference in TC level, when compared to the control group.

TABLE 3: Effect of fermented onion with *L. casei* HD-010 on serum low-density lipoprotein level in ApoE-deficient mice.

Treatment	Dose (mg/kg/day)	Low density lipoprotein (LDL, mg/dl)						
		0 weeks	1 week	2 weeks	3 weeks	4 weeks	5 weeks	6 weeks
Control	0	575.9±51.05	620.0±96.49	536.6±93.56	621.9±47.44	509.8±67.23	675.9±54.93	592.4±37.39
Low	25	581.4±81.00	624.1±58.78	462.3±72.85 [#]	624.4±26.62	484.6±52.17 [#]	517.0±92.00 [*]	553.5±40.53
Mid	50	532.6±81.58	605.1±63.79	441.3±72.70 [#]	597.1±55.23 [#]	477.1±98.76 [#]	486.7±59.18 ^{***#}	547.4±31.61 [*]
High	100	517.0±39.48	595.9±64.42	336.4±62.60 ^{***#}	591.0±89.04 [#]	454.9±20.30 [#]	484.2±69.66 ^{***#}	500.3±77.92 ^{**#}
<i>L. casei</i> KCTC 2180	100	612.6±60.79	677.9±114.79	593.6±47.41	723.1±28.63 ^{**}	625.6±55.93 [*]	685.7±72.79	624.0±26.55
Benzafibrate	10	597.3±90.47	581.8±40.11	513.4±67.09	652.3±83.81	649.9±69.99 [*]	652.4±76.33	590.0±24.63

Data are presented as mean ± SD (10 animals per group; three independent experiments were performed).

Statistical significance between control and treated values was determined by two-tailed Student's *t*-test with *p* value; **p* value < 0.05 and ***p* value < 0.001 (versus control group); #*p* value < 0.05 and ##*p* value < 0.001 (versus *L. casei* KCTC 2180 and benzafibrate treated group).

TABLE 4: Effect of fermented onion with *L. casei* HD-010 on serum high-density lipoprotein level in ApoE-deficient mice.

Treatment	Dose (mg/kg/day)	High density lipoprotein (HDL, mg/ dl)						
		0 weeks	1 week	2 weeks	3 weeks	4 weeks	5 weeks	6 weeks
Control	0	45.5±7.41	47.1±1.05	44.3±8.95	50.8±3.20	36.0±4.23	31.4±4.43	44.8±2.27
Low	25	45.5±1.06	50.7±1.91**	46.2±7.38	57.4±1.28**	56.6±9.70**	48.0±9.51**	45.6±8.59
Mid	50	52.8±3.02	58.2±3.77**	52.9±6.82#	65.3±0.92**	58.6±4.10**	51.8±3.41**	56.2±7.73***
High	100	56.6±8.96	64.2±6.00***	55.4±6.81##	70.3±3.64***	66.3±4.18***	62.5±5.13***	56.6±1.98**
<i>L. casei</i> KCTC 2180	100	45.2±3.90	52.7±3.95*	38.9±5.06	54.4±2.40	46.3±6.13*	48.8±8.62**	43.6±6.55
Benzafibrate	10	43.2±2.95	48.0±2.99	39.1±5.29	55.7±4.66	35.8±0.92**	32.1±5.85	42.7±6.30

Data are presented as mean ± SD (10 animals per group; three independent experiments were performed).

Statistical significance between control and treated values was determined by two-tailed Student's *t*-test and is given as a *p* value; **p* value < 0.05 and ***p* value < 0.001 (versus control group); #*p* value < 0.05 and ##*p* value < 0.001 (versus *L. casei* KCTC 2180 and benzafibrate treated group).

TABLE 5: Effect of fermented onion with *L. casei* HD-010 on serum triglyceride level in ApoE-deficient mice.

Treatment	Dose (mg/kg/day)	Triglyceride (TG, mg/ dl)						
		0 weeks	1 week	2 weeks	3 weeks	4 weeks	5 weeks	6 weeks
Control	0	406.6±35.68	561.2±54.01	334.4±60.37	652.3±65.16	302.3±48.56	412.2±75.99	284.8±54.11
Low	25	379.1±76.36	553.5±70.59	301.0±75.14	628.2±63.90	288.3±45.88	396.2±59.68	266.6±23.08
Mid	50	363.5±64.19	461.6±99.73	270.1±16.91	581.1±34.41	283.1±43.47	321.0±82.27	265.7±16.24
High	100	395.5±61.04	449.7±59.96*	228.5±42.10*	537.3±62.24*	273.4±60.84	241.5±68.03**	252.5±39.91
<i>L. casei</i> KCTC 2180	100	410.4±78.77	475.9±41.84*	275.2±37.67	507.0±24.04**	241.7±57.09	255.9±65.39**	270.3±26.89
Benzafibrate	10	380.5±86.76	529.5±90.37	285.3±52.13	656.7±71.61	257.2±33.35	396.9±99.12	273.6±39.73

Data are presented as mean ± SD (10 animals per group; three independent experiments were performed).

Statistical significance between control and treated values was determined by two-tailed Student's *t*-test and is given as a *p* value; **p* value < 0.05 and ***p* value < 0.001.

TABLE 6: Effect of fermented onion with *L. casei* HD-010 on serum total cholesterol level in ApoE-deficient mice.

Treatment	Dose (mg/kg/day)	Total Cholesterol (TC, mg/dl)						
		0 weeks	1 week	2 weeks	3 weeks	4 weeks	5 weeks	6 weeks
Control	0	702.7±40.72	779.4±88.99	647.8±89.39	803.2±41.15	621.8±71.15	789.7±55.05	699.1±41.20
Low	25	702.7±88.48	785.5±63.45	568.7±82.61	807.5±19.50	598.8±46.83	644.3±79.84*	644.8±39.13*
Mid	50	658.1±73.41	755.7±51.34	548.3±67.92	778.6±57.04	592.3±91.15	602.7±62.89**	641.1±60.00*
High	100	652.7±28.06	750.1±60.31	437.4±61.70***	768.7±83.53#	575.9±20.40#	595.0±73.14***	619.4±78.28*
<i>L. casei</i> KCTC 2180	100	739.9±48.37	825.8±113.75	687.6±52.21	879.0±32.08*	720.2±66.89	785.8±79.01	715.2±33.01
Benzafibrate	10	716.6±90.81	735.7±26.94	609.5±66.18	839.3±92.52	737.1±73.97*	763.9±87.42	687.4±19.36

Data represent mean ± SD (10 animals per group; three independent experiments were performed).

Statistical significance between control and treated values was determined by two-tailed Student's *t*-test and is given as a *p* value; **p* value < 0.05 and ***p* value < 0.001 (versus control group); #*p* value < 0.05 and ##*p* value < 0.001 (versus *L. casei* KCTC 2180 and benzafibrate treated group).




FIGURE 5: Effect of fermented onion with *L. casei* HD-010 on serum CETP and HMG- CoA reductase activity in ApoE-deficient mice at six weeks. Data are presented as mean ± SD (10 animals per group; three independent experiments were performed). Statistical significance between untreated and treated values was determined by two-tailed Student's *t*-test and is given as a *p* value; **p* value < 0.05 and ***p* value < 0.001 (versus control group); #*p* value < 0.05 and ##*p* value < 0.001 (versus *L. casei* KCTC 2180 and benzafibrate treated group).

We used ApoE-deficient mice model in order to assess the efficiency of fermented onion extract on reducing lipid accumulation, HMG-CoA reductase inhibition, and CETP inhibition. HMG-CoA reductase is involved in cholesterol synthesis [13, 28]. It was reduced following fermented onion extract administration. However, such decrease was not statistically significant (Figure 5). CETP protein works as a carrier for HDL and LDL into the body [3, 29] and

HMG-CoA reductase is involved in cholesterol synthesis [13, 28]. As shown in Figure 5, CETP activity and HMG-CoA reductase were significantly following fermented onion extract administration (Figure 5). These data suggest that fermented onion extract can efficiently block intestinal fat adsorption through inhibition of CETP activity.

Hyperlipidemia is an important issue in healthcare. It is involved in many serious cardiovascular diseases. Many

experimental and clinical studies have shown that hyperlipidemia may cause hypertension, diabetes, and obesity [4, 6, 7, 19].

Many studies have reported that onion components or *Lactobacillus* can lower lipid contents in blood. Onion is a well-known traditional medicine. It has been investigated for many epidemiologic studies [19, 30]. In Asian countries, onion and garlic plants that contain diallyl sulfide and quercetin are used to prevent cardiovascular diseases. Onion contains about 90% water, 7 ~8% sugar (mainly fructose), and minor amounts of vitamins [29, 31]. S-methyl-L-cysteine sulphoxide is one of the components in onion. It can reduce lipid contents in blood [14, 16]. Quercetin has a similar effect in reducing lipid production and synthesis in animal experiment [32]. *Lactobacillus* can also reduce cholesterol level in blood. Many studies have shown that *Lactobacillus* can inhibit bile acid reabsorption and attachment of cholesterol onto cell wall [33, 34]. However, fermented onion extract has not yet been studied well. Few research groups have attempted to develop fermented onion extract drink product.

In this study, we attempted to identify a proper bacterium for onion fermentation and determine its effect on blood lipid level. Our data suggest that fermented onion extract has an effect on lipid metabolism by oral administration.

4. Conclusions

The main active material responsible for the antihyperlipidemia effect of fermented onion was quercetin. Our results suggest that fermented onion has preventive/therapeutic effect on hyperlipidemic disease. It might have potential to be developed as a functional food.

Data Availability

The data are linked to online repositories of <http://www.nodaji.net>.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors' Contributions

Woong-Suk Yang and Jin-Chul Kim contributed equally to this work.

Acknowledgments

The present study was in part supported by Nodaji Co. Ltd., (Pohang, Korea) in year 2012.

References

- [1] U. Alexy, W. Sichert-Hellert, and M. Kersting, "Fifteen-year time trends in energy and macronutrient intake in German children and adolescents: Results of the DONALD study," *British Journal of Nutrition*, vol. 87, no. 6, pp. 595–604, 2002.
- [2] V. Lanzotti, "The analysis of onion and garlic," *Journal of Chromatography A*, vol. 1112, no. 1-2, pp. 3–22, 2006.
- [3] C. Oh, J.-K. No, and H.-S. Kim, "Dietary pattern classifications with nutrient intake and body composition changes in Korean elderly," *Nutrition Research and Practice*, vol. 8, no. 2, pp. 192–197, 2014.
- [4] L. E. H. Bakker, L. D. Van Schinkel, B. Guigas et al., "A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men," *Diabetes*, vol. 63, no. 1, pp. 248–258, 2014.
- [5] J. Chen, H. Chen, S. Tsai, and C. J. Jen, "Chronic consumption of raw but not boiled welsh onion juice inhibits rat platelet function," *Journal of Nutrition*, vol. 130, no. 1, pp. 34–37, 2000.
- [6] A. O. Musaiger, "Diet and prevention of coronary heart disease in the Arab Middle East countries," *Medical Principles and Practice*, vol. 11, Supplement 2, pp. 9–16, 2002.
- [7] A. Nanri, T. Mizoue, D. Yoshida, R. Takahashi, and R. Takayanagi, "Dietary patterns and AIC in Japanese men and women," *Diabetes Care*, vol. 31, no. 8, pp. 1568–1573, 2008.
- [8] T. Funatsu, H. Kakuta, H. Tanaka, Y. Arai, K. Suzuki, and K. Miyata, "Atorvastatin (Lipitor): a review of its pharmacological and clinical profile," *Nihon Yakurigaku Zasshi*, vol. 117, no. 1, pp. 65–76, 2001.
- [9] A. Bernardes, P. C. Souza, J. R. Muniz et al., "Molecular mechanism of peroxisome proliferator-activated receptor alpha activation by WY14643: a new mode of ligand recognition and receptor stabilization," *Journal of Molecular Biology*, vol. 425, no. 16, pp. 2878–2893, 2013.
- [10] M. Laugesen, M. Scollo, D. Sweanor et al., "World's best practice in tobacco control," *Tobacco Control*, vol. 9, no. 2, pp. 228–236, 2000.
- [11] A. Lei, Q. Yang, X. Li et al., "Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis," *The Journal of Immunology*, vol. 149, no. 4, pp. 432–446, 2016.
- [12] R. Abid, R. Mahmood, and H. S. Santosh Kumar, "Hypolipidemic and antioxidant effects of ethanol extract of *Cassia fistula* fruit in hyperlipidemic mice," *Pharmaceutical Biology*, vol. 54, no. 12, pp. 2822–2829, 2016.
- [13] G. Baskaran, S. Salvamani, S. A. Ahmad, N. A. Shaharuddin, P. D. Pattiram, and M. Y. Shukor, "HMG-CoA reductase inhibitory activity and phytochemical investigation of *Basella alba* leaf extract as a treatment for hypercholesterolemia," *Drug Design, Development and Therapy*, vol. 9, pp. 509–517, 2015.
- [14] F. A. M. Klaver and R. van der Meer, "The assumed assimilation of cholesterol by lactobacilli and *Bifidobacterium bifidum* is due to their bile salt-deconjugating activity," *Applied and Environmental Microbiology*, vol. 59, no. 4, pp. 1120–1124, 1993.
- [15] G. Y. Chang, Z. Y. Dong, W. Wang, and D. F. Wang, "Long-term follow-up of isolated-growth hormone deficiency type A: the clinical analysis of 2-sister cases," *Zhonghua Er Ke Za Zhi*, vol. 48, pp. 944–946, 2010.
- [16] I. Fasolino, A. A. Izzo, T. Clavel, B. Romano, D. Haller, and F. Borrelli, "Orally administered allyl sulfides from garlic ameliorate murine colitis," *Molecular Nutrition & Food Research*, vol. 59, no. 3, pp. 434–442, 2015.
- [17] T. Li and J. Y. L. Chiang, "Bile acids as metabolic regulators," *Current Opinion in Gastroenterology*, vol. 31, no. 2, pp. 159–165, 2015.

- [18] K. H. Hwang, L. H. Jung, N. C. Cho et al., "The effects of concentration onion juice in a body composition, serum electrolytes and lipids levels on hyperlipidemia," *The Korean Journal of Food and Nutrition*, vol. 16, pp. 36–45, 2003.
- [19] A. Khaki, A. Farnam, A. D. Badie, and H. Nikniaz, "Treatment effects of onion (*Allium cepa*) and ginger (*Zingiber officinale*) on sexual behavior of rat fater inducing an antiepileptic drug (lamotrigine)," *Balkan Medical Journal*, vol. 29, no. 3, pp. 236–242, 2012.
- [20] C. Löffelholz, S. C. Kaiser, M. Kraume, R. Eibl, and D. Eibl, "Dynamic single-use bioreactors used in modern liter-and m(3)-scale biotechnological processes: Engineering characteristics and scaling up," *Advances in Biochemical Engineering/Biotechnology*, vol. 138, pp. 1–44, 2014.
- [21] J. R. Vallejos, S. Uplekar, J. F. da Silva, K. A. Brorson, A. R. Moreira, and G. Rao, "A case study in converting disposable process scouting devices into disposable bioreactors as a future bioprocessing tool," *Biotechnology and Bioengineering*, vol. 109, no. 11, pp. 2790–2797, 2012.
- [22] K. M. Gillespie, J. M. Chae, and E. A. Ainsworth, "Rapid measurement of total antioxidant capacity in plants," *Nature Protocols*, vol. 2, no. 4, pp. 867–870, 2007.
- [23] W.-S. Yang, S.-H. Yang, J.-Y. Lee, S.-H. Jang, C.-H. Kim, and C.-W. Hwang, "Anti-oxidative and anti-microbial activities of purified MPN-1-1 from *Persicarianepalensis* (Meisn.) Miyabe," *Current Pharmaceutical Biotechnology*, vol. 18, no. 7, pp. 552–559, 2017.
- [24] W.-S. Yang, I. Kim, Y.-B. Seu et al., "Ethanolic extract of radish sprout (*Raphanussativus* L.) prevents bisphenol A-induced testicular dysfunction in male rats," *Journal Food Biochemistry*, vol. 40, no. 4, pp. 490–498, 2016.
- [25] W. S. Yang, S. R. Lee, Y. J. Jeong et al., "Antiallergic activity of ethanol extracts of *Arctiumlappa* L. undried roots and its active compound, oleamide, in regulating Fc γ RI-mediated and MAPK signaling in RBL-2H3 cells," *Journal of Agricultural and Food Chemistry*, vol. 64, no. 18, pp. 3564–3573, 2016.
- [26] A. Crozier, M. E. J. Lean, M. S. McDonald, and C. Black, "Quantitative analysis of the flavonoid content of commercial tomatoes, onions, lettuce and celery," *Journal of Agricultural and Food Chemistry*, vol. 45, no. 3, pp. 590–595, 1997.
- [27] W. H. Briggs, J. D. Folts, H. E. Osman, and I. L. Goldman, "Administration of raw onion inhibits platelet-mediated thrombosis in dogs," *The Journal of Nutrition*, vol. 131, no. 10, pp. 2619–2622, 2001.
- [28] G. Griffiths, L. Trueman, T. Growther, B. Thomas, and B. Smith, "Onion-a global benefit to health," *Phytotherapy Research*, vol. 16, pp. 603–615, 2002.
- [29] M. Thomson, T. Mustafa, and M. Ali, "Thromboxane-B2 levels in serum of rabbits receiving a single intravenous dose of aqueous extract of garlic and onion," *Prostaglandins, Leukotrienes and Essential Fatty Acids*, vol. 63, no. 4, pp. 217–221, 2000.
- [30] K. Kumari and K. T. Augusti, "Lipid lowering effect of S-methyl cysteine sulfoxide from *Allium cepa* Linn in high cholesterol diet fed rats," *Journal of Ethnopharmacology*, vol. 109, no. 3, pp. 367–371, 2007.
- [31] M. Ali, M. Thomson, and M. Afzal, "Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance," *Prostaglandins, Leukotrienes and Essential Fatty Acids*, vol. 62, no. 2, pp. 55–73, 2000.
- [32] P. S. M. Prince and B. Sathya, "Pretreatment with quercetin ameliorates lipids, lipoproteins and marker enzymes of lipid metabolism in isoproterenol treated cardiotoxic male Wistar rats," *European Journal of Pharmacology*, vol. 635, no. 1-3, pp. 142–148, 2010.
- [33] T. Baptista, N. M. K. N. Y. Kin, S. Beaulieu, and E. A. De Baptista, "Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives," *Pharmacopsychiatry*, vol. 35, no. 6, pp. 205–219, 2002.
- [34] C. C. Tsai, P. P. Lin, Y. M. Hsieh, Z. Y. Zhang, H. C. Wu, and C. C. Huang, "Cholesterol-lowering potentials of lactic acid bacteria based on bile-salt hydrolase activity and effect of potent strains on cholesterol metabolism in vitro and in vivo," *Scientific World Journal*, vol. 34, no. 1, pp. 196–201, 2014.